



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 755 924 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
09.06.1999 Bulletin 1999/23

(51) Int. Cl.⁶: C07D 213/20, A61K 31/44

(21) Application number: 96202095.4

(22) Date of filing: 24.07.1996

(54) Transportvehicles for macromolecules

Transportvehikel für Makromoleküle

Véhicules de transport pour macromolécules

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority: 25.07.1995 NL 1000884

(43) Date of publication of application:
29.01.1997 Bulletin 1997/05

(73) Proprietors:

- Stichting voor de Technische Wetenschappen
3502 GA Utrecht (NL)
- Rijksuniversiteit te Groningen
9712 CP Groningen (NL)
- STICHTING SCHEIKUNDIG ONDERZOEK IN
NEDERLAND (SON)
2509 AC Den Haag (NL)

(72) Inventors:

- Engberts, Jan Bernard Frederik Nicolaas
9742 EC Groningen (NL)
- Wagenaar, Anno
9982 HT Ulthulzerveen (NL)
- Hoekstra, Dirk
9801 GJ Zuidhorn (NL)
- van der Woude, Irene
9716 EH Groningen (NL)
- Rulters, Marcel Herman Jozef
9801 LK Zuidhorn (NL)

(74) Representative: Kupecz, Arpad
Octrooibureau Los en Stigter B.V.
Postbox 20052
1000 HB Amsterdam (NL)

(56) References cited:
EP-A- 0 516 194

- CHEMICAL ABSTRACTS, vol. 112, no. 1, 1
January 1990 Columbus, Ohio, US; abstract no.
7383a, N.S. BODOR : "Preparation of
dihydropyridine-containing prodrugs for
brain-specific drug delivery." page 724;
XP002017482 & US-A-4 824 850 (UNIVERSITY OF
FLORIDA)
- CHEMICAL ABSTRACTS, vol. 96, no. 22, 31 May
1982 Columbus, Ohio, US; abstract no. 191111b,
E.J.R. SUDHOLTER ET AL.: "Thermotropic
liquid-crystalline behavior of some single- and
double-chained pyridinium amphiphiles." page
703; XP002017483 & JOURNAL OF PHYSICAL
CHEMISTRY, vol. 86, no. 10, 1982,
WASHINGTON, D.C., pages 1908-1913,
• Proc.Natl.Acad.Sci., U.S.A., (1987), vol.
84,p.7413-7417

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 755 924 B1

Description

[0001] The present invention relates to new compounds which are capable of introducing macromolecules into eucaryotic cells.

[0002] The introduction of macromolecules, including DNA, proteins and the like, into eucaryotic cells can be carried out in different ways, for instance by means of transport vehicles. Such vehicles introduce a molecule into the cell, for instance by means of endocytosis. The vehicles may bind, but for instance also encapsulate, the molecules to be transported. In the latter case the vehicles are referred to as vesicles. Known vesicles are liposomes which consist of a bilayer of phospholipids.

[0003] EP-A516 194 discloses cationic amphiphilic compounds containing pharmaceutical preparations which furthermore contain one monovalent anion and an antiviral compound.

[0004] US-A-4,824,850 describes compounds which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain.

[0005] Liposomes are for instance used to introduce medicines into the cell. It appeared that liposomes are incorporated into the cell both *in vivo* and *in vitro* by means of endocytosis (Nandi, P.K. et al. (1986) J. Biol. Chem. 261: 16722; Heath, T.D. (1987) Methods Enzymol. 149:111). This means that the largest portion of the material which is incorporated in the cell will ultimately appear in the lysosomal apparatus, where it will be decomposed. Particularly for substances which have their effect in the cytoplasm or the nucleus this is obviously very disadvantageous.

[0006] If the substances to be introduced are hydrophilic it will be difficult to introduce them into liposomes. The main portion of the material remains in the aqueous phase. Particularly in case of expensive substances, like probes and many medicines, this is an obvious disadvantage.

[0007] To prevent that the substances to be introduced into the cell end up in the cell by means of endocytosis, attempts have been made to use fusogenic phospholipids as transport vehicles. The use of fusogenic phospholipids should result in fusion of the from the fusogenic phospholipids formed vesicles with the cell membrane and thus introduce their contents into the cell. However, such attempts have not proven to be very successful because fusogenic liposomes have a strong tendency to mutually merge instead of fusing with the cell membrane (Fontein, T.A.A., Ph.D. Thesis (1992)).

[0008] One of the most important applications in which molecules are introduced into a cell is transfection of the (eucaryotic) cell with DNA or RNA. Transfection is being used for studying the function and regulation of genes and proteins, but also for the genetic modification of microorganisms, plants and animals. There is a large number of artificial techniques which allow DNA to be introduced into a cell, including DNA-micro-injection, DNA-coprecipitation within inorganic salts or with polycations, DNA-encapsulation in liposomes, and making the cell membrane permeable with the aid of chemical or physical means.

[0009] A more recent technique (Felgner, P.L. et al., Proc. Natl. Acad. Sci. U.S.A. 1987 vol. 84, 7413-7417) involves the use of cationic amphiphilic molecules as transport vehicles. One of the best-known amphiphiles is the quaternary ammonium amphiphile DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) which in combination with dioleoyl phosphatidyl ethanolamine (DOPE), is commercially available with the name Lipofectine™. Both molecules are lipidic (analogues), which form liposomes, which will form complexes with the negatively charged nucleic acids. Supposedly, the liposomes merge with the plasma membrane and introduce in this way nucleic acids into the cell. However, it could also be done by means of endocytosis. The exact mechanism is yet unknown. With the aid of Lipofectine™ the transfection efficiency may be enhanced by a factor of 30 with respect to other known systems, including the classical calcium phosphate precipitation method. However, the disadvantage of Lipofectine™ is its toxicity and therefore it may be difficult or not possible to use it *in vivo*. Therefore, a demand still remains for other and better transfection methods.

[0010] It is the aim of the present invention to provide new cationic amphiphilic compounds, which allow high efficiencies, for the introduction into a cell of nucleic acids and other macromolecules, including for example proteins and medicines.

[0011] The aim is achieved by the invention by compounds according to claim 1. Preferred compounds are the subject of the claims 2 to 13. A particularly advantageous compound according to the invention is 1-methyl-4-(19-*cis,cis*-heptatriaconta-9,28-dienyl) pyridinium chloride (SAINT-2). The compounds according to the invention are all based on a pyridine ring, which is at one or two positions substituted by a long (ar)alkyl chain. It has been found that with the amphiphiles according to the invention, and particularly with the compound here referred to as "SAINT-2", a transfection efficiency can be obtained which, dependent on the cell type, is at least eight times higher as that of Lipofectine™.

[0012] With SAINT-2/DOPE it also proved to be possible to introduce proteins, particularly gelonine (30kD), into the cell. Other cell types, particularly Baby Hamster Kidney (BHK) cells, may be transfected. This is impossible with Lipofectine™ for BHK cells. SAINT-2/DOPE yields even better results with BHK cells than Lipofectine™ with COS-7 cells.

[0013] The compounds according to the invention may be synthesized in a well-known fashion. The synthesis will be further illustrated in the examples.

[0014] The amphiphiles according to the invention may be used in a large number of applications.

[0015] The transport into the cell of nucleic acids and their derivatives is of importance for transfection. The aim of transfection is, for instance, to make proteins or to perform research. Furthermore, transfected nucleic acids, possibly labelled with streptavidine or radioactively labelled, may be used for *in situ* hybridisation. A more advanced application is to influence gene expression, for instance blocking of genes by antisense strands. Furthermore, gene expression may also be stimulated. Furthermore, the defect genes may be replaced. The latter two applications are of particular importance in gene therapy.

[0016] The advantage of compounds according to the invention is that they, as compared to the known transport vehicles, can be used in much lower, non-toxic concentrations. Probably, they also do not cause an immunologic response.

[0017] If DNA and/or RNA are to be introduced into a cell the compounds and the nucleic acids have to be mixed in a certain ratio. It has been found that for the known amphiphiles, including DOTMA, there exists an optimum amphiphile concentration (Felgner, P.L. et al. (1987) Proc. Natl. Acad. Sci. USA 84:7413). The transfection efficiency again reduces if a certain amount is exceeded. A comparable situation also holds for the compounds according to the invention.

[0018] The cationic amphiphiles according to the invention may also be used to transport negatively charged proteins, including gelonine in particular, into the cell.

[0019] The amphiphiles may also be used to transport substances like cytostatics. Lipophilic cytostatics in particular do interact with the compounds according to the invention and may in this way be introduced into the cell very efficiently.

[0020] In a preferred embodiment of the invention the transport vehicles may be purposely brought to a specific site by mixing the amphiphiles with a targeting molecule, such as, for instance, an antibody which is directed against an epitope in the neighbourhood of the site where the incorporated substance has to exercise its activity. The antibody is preferably coupled to the amphiphilic compound but it may also be coupled, for instance, through a spacer, to the substance to be transported. In order to facilitate the translocations of DNA or other macromolecules across the cell membrane the compounds according to the invention may also be mixed with a phospholipid or with each other.


[0021] The present invention will be illustrated in further detail with by means of the accompanying examples which are only serve as an illustration and do not limit the scope of the invention.

EXAMPLES

EXAMPLE 1

Synthesis

[0022] Compounds with the general structure formula




may be divided in a number of groups dependent on their substituents. The synthesis of four of those groups will be given below as an example.

1. 4-Substituted N-alkylpyridinium salts.

1.1. Synthesis of 1-methyl-4-(1-octadecylnonadecyl)pyridinium chloride.

[0023] The compound is synthesised according to scheme 1 below as described by E.J.R. Sudhölter in his Ph.D. thesis at the University of Groningen, 1981, page 37.


Scheme 1:



1.2. Synthesis of 1-methyl-4-(19-cis,cis-heptatriaconta-9,28-dienyl)pyridinium chloride (SAINT-2).

[0024] Scheme 2 describes the sequence of the reactions.

Scheme 2:



[0025] The synthesis has been carried out under nitrogen. 2.226 g (0.022 mol) of di-isopropyl amine was dissolved in 15 ml of dry diethyl ether. Then 13.8 ml (1.6 M) n-butyl lithium in n-hexane was added dropwise at 0°C. Subsequently, the mixture was stirred for 10 minutes. This mixture was added dropwise to 0.931 g (0.01 mol) 4-picoline in 10 ml of diethyl ether at -20°C. After this it was stirred for another 30 minutes. The colour of the reaction mixture became deeply orange. Then 7.567 g (0.020 mol) oleyl iodide (85% cis) in 5 ml of diethyl ether was added one portion. The temperature increased to 0°C while stirring. Subsequently, the mixture was stirred during one night at room temperature. The next day 100 ml of diethyl ether was added to the reaction mixture and subsequently 40 ml of H₂O. The organic layer was separated and washed with 3 portions of 30 ml H₂O. The ether layer was dried on Na₂SO₄, filtered and condensed. The residu (5.9 g) is a viscous brown oil which was purified over a column of 100 g neutral Al₂O₃ (act. 2-3). As eluent a mixture of n-hexane-diethyl ether (8:2) was used. 4.32 g (0.0073 mol) 4-(19-cis,cis-heptatriaconta-9,28-dienyl)pyridine was obtained (intermediate 1b2, yield 73%).

[0026] NMR data: ¹H NMR(CDCl₃): δ 0.89 (t, 6H); 1.27 (chain, 52H); 2.0 (m, 8H); 2.43 (tr. 1H); 5.34 (m, 4H); 7.06 (d, J_{H,H}=6Hz, 2H); 8.49 (d, J_{H,H}=6Hz, 2H). ¹³C NMR: δ 14.0 (CH₃); 22.6; 27.1; 27.3; 29.1; 29.2; 29.4; 29.5; 29.6; 29.7; 31.8; 36.1 (CH₂-chain); 45.5 (CH); 123.1 (CH); 129.7 (CH); 129.8 (CH); 149.5 (CH); 155.3 (C).

[0027] 1.527 g (0.0025 mol) of intermediate 1 was dissolved in 10 ml of acetone. Subsequently, 2 ml of methyl iodide was added and the mixture was boiled for 3 hours. After evaporation of the solvent a light yellow brown viscous oil was obtained with a yield of 0.8 g (intermediate 1b1, yield 97%).

[0028] NMR data: ¹H NMR(CDCl₃): δ 0.85 (t, 6H); 1.23 (chain, 44H); 1.55 (m, 4H); 1.73 (m, 4H); 2.00 (m, 8H); 2.77 (m, 1H); 4.7 (2, 3H); 5.31 (m, 4H); 7.74 (d, J_{H,H}=6.7Hz, 2H); 9.31 (d, J_{H,H}=6.7Hz, 2H). ¹³C NMR: δ 13.9 (CH₃); 22.4; 26.9; 27.2; 28.9; 29.1; 29.3; 29.4; 29.5; 31.6; 35.4 (CH₂-chain); 46.4 (CH); 48.3 (N-CH₃); 126.8 (CH); 129.5 (CH); 129.7 (CH); 144.9 (CH); 167.1 (C).


[0029] 0.4 g (0.00054 mol) of intermediate 2 was dissolved in 3 ml of methanol and this solution was eluted with methanol over a Dowex column (1*8, 200-400 mesh Cl⁻ form). The compound 1b was obtained as a viscous oil in a yield of 0.319 g (0.00049 mol 92%).

[0030] NMR data: ¹H NMR(CDCl₃): δ 0.87 (t, 6H); 1.26 (CH₂-chain, 44H); 1.57 (m, 4H); 1.75 (m, 4H); 2.00 (m, 8H); 2.77 (m, 1H); 4.77 (s, 3H); 5.32 (m, 4H); 7.15 (d, J_{H,H}=6.2Hz, 2H); 9.50 (d, J_{H,H}=6.2Hz, 2H).

1.3. Synthesis of 1-(1-butyl-N,N,N-trimethyl ammonium)-4-(17-tritriacontanyl)pyridinium chloride.

[0031] This compound was synthesized according to scheme 3 below.


Scheme 3:



2. 3,5-Disubstituted-N-alkylpyridinium salts.

15 [0032] The general synthesis according to scheme 4 below was described in the literature by Sudhölter (*vide supra*) and Wang et al., J. Org. Chem. 42, 1286 (1977).

Scheme 4:



2.1. 1-methyl-3,5-dicarboxy-N-octadecyloxy pyridinium chloride.

35 [0033] This compound was synthesized according to scheme 4.

[0034] NMR data: ¹H NMR(CDCl₃): δ 0.85 (t, 6H); 1.30 (chain, 64H); 4.40 (t, 4H); 5.03 (s, 3H); 9.20 (t, 1H); 10.00 (d, 2H).

3. 4-Substituted-N-alkyl pyridinium salts.

[0035] The synthesis was described by F.J.A. Hundscheid and J.B.F.N. Engberts, J. Org. Chem. 49, 3088 (1984).

3.1. 1-Methyl-4-((-n-hexadecyloxy)carbonyl) pyridinium iodide.

45 [0036] The synthesis of this compound and its characterisation are described by Hundscheid and Engberts (*vide supra*).

[0037] NMR data: ¹H NMR(CDCl₃): δ 0.9 (t, 3H); 1.25 (m, 28H); 4.35 (t, 2H); 4.70 (s, 3H); 8.35 (d, 2H); 9.35 (d, 2H).

4. 4-Substituted-N-alkyl pyridinium salts.

4.1. 1-(3-phenyl-1-propyl)-4-n-dodecylpyridinium iodide.

55 [0038] The compound was synthesized by boiling a mixture of 2.26 g (9.2 mmol) 1-iodo-3-phenyl propane and 2.57 g (10.0 mmol) 4-n-dodecylpyridine in 35 ml of dry acetone for 16 hours. The solvent was evaporated and the yellow solid substance was recrystallized from THF/ether. The yield is 3.06 g (6.2 mmol), melting point 79.0-80.0°C.

[0039] NMR data: ¹H NMR(CDCl₃): δ 0.83 (t, 3H); 1.21 (chain, 20H); 1.61 (m, 2H); 2.36 (m, 2H); 2.78 (m, 2H); 4.89 (t, 2H); 7.05-7.20 (m, 5H); 7.73 (d, 2H); 9.30 (d, 2H).

EXAMPLE 2

Formation of unilamellar vesicles

5 [0040] A suitable amount of lipid was dried under $N_2(g)$. In case of combinations of substances these are first mixed and then dried. The lipid film layer is subsequently dried further under vacuum. The lipids are then suspended, vortexed and subsequently sonicated in a suitable volume of water until the solution is clear.

EXAMPLE 3

10

Transfection of eucaryotic cells by compounds according to the invention

[0041] DNA and unilamellar vesicles, as prepared in Example 2, are both brought into Hepes buffered saline (HBS, pH 7.4; both 0.5 ml) and subsequently mixed. The DNA/amphiphile complex is directly formed. In a typical transfection experiment 1 μg of DNA and 7.5-10 μg of the amphiphile SAINT-2 (1-methyl-4-(19-*cis,cis*-heptatriacontadienyl-9-28) pyridinium chloride) or 1 μg of DNA and 10-15 μg of total amphiphile (SAINT-2/DOPE 1:1) is used.

[0042] Cells in six-well plates, which are confluent by 70-80%, are washed twice with 1 ml of HBS and subsequently 1 ml of the DNA/amphiphile complex was added per well. The cells were incubated during 4 hours at 37°C after which 1 ml Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% Foetal Calf Serum (FCS) was added. After an incubation of 16 hours at 37°C the medium was exchanged by 2 ml fresh DMEM with 10% FCS. After a subsequent incubation of 28 hours at 37°C the cells were gathered. The cells were washed twice with a phosphate buffered saline (PBS) and scraped in 300 μl 1x lysis buffer (Promega). The scraped cells were incubated for 10 minutes at 56°C and subsequently centrifuged at maximum speed for two minutes at room temperature. On the supernatant an enzyme determination (CAT-assay) and a protein determination (Lowry) were carried out.

25 [0043] 100 μl of the cell extract was incubated together with 3 μl ^{14}C -chloramphenicol (25 mCi/l), 5 μl N-butyryl-CoA (2 mg/ml) and 17 μl 0.25 M Tris.HCL (pH 8.0) during 90 minutes at 37°C. The reaction was stopped by adding 0.3 ml of mixed xylenes (Aldrich). The samples were vortexed for 30 seconds and subsequently centrifuged at maximum speed for 3 minutes at room temperature. The organic phase was again extracted with 0.1 ml 0.25 M Tris.HCL, vortexed for 30 seconds and centrifuged for 3 minutes. 4 ml of counting fluid was added to 0.2 ml of the organic phase and the radio activity was measured.

[0044] It was found that transfection of COS-7 cells with the new amphiphile (SAINT-2 and SAINT-2/DOPE) is eight times more efficient than that with DOTMA/DOPE vesicles (see Fig. 1).

[0045] It appeared that with the new amphiphile also other cell types, including for instance BHK cells, can be transfected (Fig. 2). When a stable transfection is carried out with the new amphiphile it appeared to be possible to transfect 42-45% of the COS-7 cells. With DOTMA-DOPE vesicles on average 25-29% of the cells are transfected.

EXAMPLE 4

Transport of proteins in an eucaryotic cell

40

[0046] The synthetic amphiphile SAINT-2 is, in combination with DOPE, a suitable agent for the delivery of proteins into cells. The efficiency of protein internalisation with SAINT-2/DOPE as a carrier can be monitored with the aid of the gelonine protein. Internalized gelonine specifically inhibits the protein synthesis of cells and this inhibition is a direct measure for the amount of gelonine which has been brought into the cell. Unilamellar vesicles of the synthetic agent amphiphile SAINT-2 and DOPE are obtained by bath sonication. Gelonine is added to a certain concentration (0-20 μM) SAINT-2/DOPE in HBS from a stock solution (2 mg/ml).

[0047] CV-1 cells, grown in twelve-well plates, are washed three times with HBS. Subsequently, the cells are incubated for 1 hour at 37°C with the amphiphile/gelonine complex in HBS obtained in this way. After this the cells are again washed three times with HBS.

50 [0048] The inhibition of protein synthesis by gelonine is being followed by determining the building-in of radioactively labelled methionine into the treated cells. This is carried out by incubating the cells for 30 minutes with 1 μCi ^{35}S -methionine. Subsequently, the cells are washed three times with PBS and finally scraped in 10% TCA. The cell lysate obtained in this way is washed three times with 10% TCA and the amount of radioactive methionine present in the cell lysate is determined with the aid of a scintillation counter.

55 [0049] Incubation of CV-1 cells with the amphiphile/gelonine complex gives a strong inhibition of the protein synthesis with respect to the control experiment in which the cells were incubated with the synthetic amphiphile only. At a concentration of 5 μM SAINT-2/DOPE and 1.6 μM gelonine an inhibition of protein synthesis of 50% was obtained.


EXAMPLE 5

Toxicity studies

- 5 [0050] To determine the toxicity of the compound SAINT-2 according to the invention with respect to DOTMA-DOPE, the COS-7 cells are incubated with different concentrations of both lipid samples. The residual protein content is taken as a measure for the amount of surviving cells.
- [0051] A decrease of the protein content from 2 to 1 mg/ml was observed for DOTMA-DOPE starting from 71 μ M lipid. For SAINT-2 a decrease from 2 to 1.75 mg/ml was found starting from 90 μ M.
- 10 [0052] This shows that SAINT-2 is clearly less toxic than DOTMA-DOPE.


Claims

- 15 1. Compounds with the general formula I



in which:

R_1 is a (C₁-C₅)alkyl, ar(alkyl) or an alkyl group with a cationic functional group, like




or

R_1 is (C₁-C₅alkylene) R_5 in which R_5 is a structure with the general formula I except R_1


X is a halide counter ion; chosen from Cl⁻, I⁻, Br⁻; and in which

or R_3 is hydrogen and R_2 and R_4 are identical or different and are chosen from the group, comprising branched or linear (C₁₀-C₂₀)alkyl, a mono- or polyunsaturated (C₁₀-C₂₀) alkenyl, O=C-O-alkyl,



or ar(alkyl),

or R_2 and R_4 are hydrogen and R_3 is -CH(R_5)₂ with R_5 , comprising (C₁₀-C₂₀)alkyl, mono- or polyunsaturated (C₁₀-C₂₀) alkenyl, O=C-O-alkyl,



or aralkyl,


wherein disclaimed are the compounds with the general formula I in which R_1 is CH₃, R_2 and R_4 are hydrogen, R_3 is (C₁₆H₃₃)₂CH and X is all mentioned counter ions (Cl⁻, I⁻, Br⁻) and disclaimed are the compounds in which R_1 is CH₃, R_2 and R_4 are C₁₆H₃₃-O-C(O), R_3 is hydrogen and X is all mentioned counter ions (Cl⁻, I⁻, Br⁻), and

3,5-bis[(decyloxy)-carbonyl]-1-methyl-pyridinium iodide.

2. Compounds according to claim 1, **characterized** in, that R_1 is CH_3 , R_2 and R_4 are hydrogen, R_3 is $(C_{18}H_{37})_2CH$ and X is Cl, Br, I.
3. Compounds according to claim 1, **characterized** in that R_1 is CH_3 , R_2 and R_4 are hydrogen, R_3 is $(C_{18}H_{35})_2CH$ and X is Cl, Br, I.
4. Compounds according to claim 1, **characterized** in that R_1 is $(CH_2)_4-N^+(CH_3)_3$, R_2 and R_4 are hydrogen, R_3 is $(C_{18}H_{35})_2CH$ and X is Cl, Br, I.
5. Compounds according to claim 1, **characterized** in that R_1 is CH_3 , R_2 and R_4 are $C_{18}H_{37}-O-C(O)$, R_3 is hydrogen and X is Cl, Br, I.
6. Compounds according to claim 1, **characterized** in that R_1 is CH_3 , R_2 and R_4 are $R_5-O-C(O)$, in which R_5 is a saturated $C_{10}-C_{20}$ aliphatic chain, R_3 is hydrogen and X is Cl, Br, I.
7. Compounds according to claim 1, **characterized** in that R_1 is CH_3 , R_2 and R_4 are not identical and each represents a group with the formula $R_5-O-C(O)$, in which R_5 is a $C_{10}-C_{20}$ alkyl, is, R_3 is hydrogen and X is Cl, Br, I.
8. Compounds according to claim 1, **characterized** in that R_1 is CH_3 , R_3 is a group with the formula $R_5-O-C(O)$, in which R_5 is a $C_{10}-C_{20}$ alkyl, R_2 and R_4 are hydrogen and X is Cl, Br or I.
9. Compounds according to claim 8, **characterized** in that R_5 is $C_{16}H_{33}$.
10. Compounds according to claim 1, **characterized** in that R_1 is $(CH_2)_n-C_6H_5$, in which $n = 3-6$, R_2 and R_4 are hydrogen, R_3 is alkyl or alkenyl and X is Cl, Br or I.
11. Compound according to claim 10, **characterized** in that R_1 is $(CH_2)_3-C_6H_5$, R_2 and R_4 are hydrogen, R_3 is $n-C_{12}H_{25}$ and X is Cl, Br or I.
12. Compounds according to claim 1, **characterized** in that R_1 is $(CH_2)_4$, R_2 and R_4 are hydrogen, R_3 is $(C_{18}H_{35})_2CH$, X is Cl, Br, I and R_5 is the group with the general formula I, bound through R_1 , in which R_2 and R_4 are hydrogen, R_3 is $(C_{18}H_{35})_2CH$ and X is Cl, Br, I.
13. Compounds according to one of the preceding claims for use as tool to introduce macromolecules into cells.
14. Composition to introduce macromolecules into cells, comprising vesicles or another type of aggregate formed by at least one compound according to one of the preceding claims in a solvent.
15. Composition according to claim 14, **characterised** in that at least one macromolecule is incorporated in and/or attached to the vesicles.
16. Composition according to claim 14 or 15, **characterized** in that furthermore at least one targeting molecule is attached to the vesicles.
17. Composition according to claim 15, **characterized** in that the targeting molecule is an antibody.
18. Composition according to claim 16, **characterized** in that the antibody is radioactively labelled or labelled with streptavidine.


Patentansprüche

1. Verbindungen mit der allgemeinen Formel I




10 in der:

R_1 eine (C_1-C_5) Alkyl-, Ar(alkyl)- oder eine Alkyl-Gruppe mit einer kationischen funktionellen Gruppe wie




ist; oder in der R_1 (C_1-C_5) -Alkylen) R_5 ist, worin R_5 eine Struktur mit der allgemeinen Formel I ohne R_1 ist, X ein Halogenid-Gegenion ist, das ausgewählt ist aus Cl^- , I^- , Br^- ; und in der R_3 Wasserstoff ist und R_2 und R_4 gleich oder verschieden sind und ausgewählt sind aus der Gruppe, die verzweigtes oder lineares $(C_{10}-C_{20})$ Alkyl, ein mono- oder polyungesättigtes $(C_{10}-C_{20})$ Alkenyl, $O=C-O$ -Alkyl,



oder Ar(alkyl) aufweist,

oder in der R_2 und R_4 Wasserstoff sind und $R_3-CH(R_5)_2$ ist, wobei R_5 $(C_{10}-C_{20})$ Alkyl, mono- oder polyungesättigtes $(C_{10}-C_{20})$ Alkenyl, $O=C-O$ -Alkyl,



oder Aralkyl aufweist,


unter Ausschluß der Verbindungen mit der allgemeinen Formel I, in denen R_1 CH_3 ist, R_2 und R_4 Wasserstoff sind, R_3 $(C_{16}H_{33})_2CH$ ist und X alle aufgeführten Gegenionen (Cl^- , I^- , Br^-) ist, und unter Ausschluß der Verbindungen, in denen R_1 CH_3 ist, R_2 und R_4 $C_{16}H_{33}-O-C(O)$ sind, R_3 Wasserstoff ist und X alle aufgeführten Gegenionen (Cl^- , I^- , Br^-) ist, und 3,5-Bis[(decyloxy)-carbonyl]-1-methyl-pyridinium-iodid.

- 40
2. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 CH_3 ist, R_2 und R_4 Wasserstoff sind, R_3 $(C_{18}H_{37})_2CH$ ist und X Cl^- , Br^- , I^- ist.
 3. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 CH_3 ist, R_2 und R_4 Wasserstoff sind, R_3 $(C_{18}H_{35})_2CH$ ist und X Cl^- , Br^- , I^- ist.
 4. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 $(CH_3)_4-N^+(CH_3)_3$ ist, R_2 und R_4 Wasserstoff sind, R_3 $(C_{18}H_{35})_2CH$ ist und X Cl^- , Br^- , I^- ist.
 - 50 5. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 CH_3 ist, R_2 und R_4 $C_{16}H_{37}-O-C(O)$ sind, R_3 Wasserstoff ist und X Cl^- , Br^- , I^- ist.
 6. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 CH_3 ist, R_2 und R_4 $R_5-O-C(O)$ sind, worin R_5 eine gesättigte, aliphatische $C_{10}-C_{20}$ -Kette ist, R_3 Wasserstoff ist und X Cl^- , Br^- , I^- ist.
 - 55 7. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 CH_3 ist, R_2 und R_4 nicht gleich sind und jedes eine Gruppe mit der Formel $R_5-O-C(O)$ darstellt, worin R_5 ein $C_{10}-C_{20}$ -Alkyl ist, R_3 Wasserstoff ist und X Cl^- , Br^- , I^- ist.

8. Verbindung nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 CH_3 ist, R_3 eine Gruppe mit der Formel $R_5\text{-O-C(O)}$ ist, worin R_5 ein $\text{C}_{10}\text{-C}_{20}$ -Alkyl ist, R_2 und R_4 Wasserstoff sind und X Cl^- , Br^- oder I^- ist.
9. Verbindungen nach Anspruch 8, **dadurch gekennzeichnet**, daß R_5 $\text{C}_{16}\text{H}_{33}$ ist.
10. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 $(\text{CH}_2)_n\text{-C}_6\text{H}_5$ ist, worin $n = 3\text{-}6$, R_2 und R_4 Wasserstoff sind, R_3 Alkyl oder Alkenyl ist und X Cl^- , Br^- oder I^- ist.
11. Verbindung nach Anspruch 10, **dadurch gekennzeichnet**, daß R_1 $(\text{CH})_3\text{-C}_6\text{H}_5$ ist, R_2 und R_4 Wasserstoff sind, R_3 $n\text{-C}_{12}\text{H}_{25}$ ist und X Cl^- , Br^- oder I^- ist.
12. Verbindungen nach Anspruch 1, **dadurch gekennzeichnet**, daß R_1 $(\text{CH}_2)_4$ ist, R_2 und R_4 Wasserstoff sind, R_3 $(\text{C}_{18}\text{H}_{35})_2\text{CH}$ ist, X Cl^- , Br^- , I^- ist, und R_5 die Gruppe mit der allgemeinen Formel I ist, die über R_1 gebunden ist, worin R_2 und R_4 Wasserstoff sind, R_3 $(\text{C}_{18}\text{H}_{35})_2\text{CH}$ ist und X Cl^- , Br^- , I^- ist.
13. Verbindungen nach einem der vorangehenden Ansprüche zur Verwendung als ein Hilfsmittel zum Einführen von Makromolekülen in Zellen.
14. Zusammensetzung zur Einführung von Makromolekülen in Zellen, die Vesikel oder eine andere Art von mittels mindestens einer Verbindung gemäß einem der vorangehenden Ansprüche gebildetem Aggregat in einem Lösungsmittel aufweist.
15. Zusammensetzung nach Anspruch 14, **dadurch gekennzeichnet**, daß mindestens ein Makromolekül in die Vesikel inkorporiert und/oder an die Vesikel gebunden ist.
16. Zusammensetzung nach Anspruch 14 oder 15, **dadurch gekennzeichnet**, daß außerdem mindestens ein Zielfindungsmolekül an die Vesikel gebunden ist.
17. Zusammensetzung nach Anspruch 15, **dadurch gekennzeichnet**, daß Zielfindungsmolekül ein Antikörper ist.
18. Zusammensetzung nach Anspruch 16, **dadurch gekennzeichnet**, daß der Antikörper radioaktiv markiert oder mit Streptavidin markiert ist.


Revendications

1. Composés répondant à la formule générale I



dans laquelle :

R_1 représente un groupe alkyle en C_1 à C_5 , Ar(alkyle) ou un groupe alkyle avec un groupe fonctionnel cationique, tel qu'un groupe



ou bien

R_1 représente un groupe (alkylène en C_1 à C_5) R_5 dans lequel R_5 représente une structure de la formule

générale I, à l'exception de R_1 ;

X représente un ion complémentaire halogénure, choisi entre Cl⁻, I⁻ et Br⁻ ; et dans laquelle

soit R_3 représente l'hydrogène et R_2 et R_4 sont identiques ou différents et sont choisis dans le groupe comprenant des radicaux alkyle en C_{10} à C_{20} ramifiés ou linéaires, un radical alcényle en C_{10} à C_{20} mono- ou polyinsaturé, un radical O=C-O-alkyle, un radical

O-C-alkyle



ou un radical Ar(alkyle),

soit R_2 et R_4 représentent l'hydrogène et R_3 représente un groupe -CH(R_5)₂ dans lequel R_5 comprend un groupe alkyle en C_{10} à C_{20} , alcényle en C_{10} à C_{20} mono- ou polyinsaturé, O=C-O-alkyle,

O-C-alkyle,



ou aralkyle,


à l'exception des composés de formule générale I dans laquelle R_1 représente un groupe CH₃, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe (C₁₆H₃₃)₂CH et X représente tous les ions complémentaires précités (Cl⁻, I⁻ et Br⁻), et

à l'exception des composés dans lesquels R_1 représente un groupe CH₃, R_2 et R_4 représentent des groupes C₁₆H₃₃-O-C(O), R_3 représente l'hydrogène et X représente tous les ions complémentaires précités (Cl⁻, I⁻ et Br⁻) et de l'iodure de 3,5-bis [(décyloxy)-carbonyl]-1-méthyl-pyridinium.


2. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe CH₃, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe (C₁₈H₃₇)₂CH et X représente Cl⁻, Br⁻ ou I⁻.
3. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe CH₃, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe (C₁₈H₃₅)₂CH et X représente Cl⁻, Br⁻ ou I⁻.
4. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe (CH₂)₄-N⁺(CH₃)₃, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe (C₁₈H₃₅)₂CH et X représente Cl⁻, Br⁻ ou I⁻.
5. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe CH₃, R_2 et R_4 représentent un groupe (C₁₈H₃₇-O-C(O), R_3 représente l'hydrogène et X représente Cl⁻, Br⁻ ou I⁻.
6. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe CH₃, R_2 et R_4 représentent des groupes R₅-O-C(O) dans lesquels R₅ représente une chaîne aliphatique en C₁₀ à C₂₀ saturée, R_3 représente l'hydrogène et X représente un groupe Cl⁻, Br⁻ ou I⁻.
7. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe CH₃, R_2 et R_4 ne sont pas identiques et représentent chacun un groupe de formule R₅-O-C(O), dans laquelle R₅ représente un groupe alkyle en C₁₀ à C₂₀, R_3 représente l'hydrogène et X représente Cl⁻, Br⁻ ou I⁻.
8. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe CH₃, R_3 représente un groupe de formule R₅-O-C(O), dans laquelle R₅ représente un groupe alkyle en C₁₀ à C₂₀, R_2 et R_4 représentent l'hydrogène et X représente Cl⁻, Br⁻ ou I⁻.
9. Composés suivant la revendication 8, caractérisés en ce que R₅ représente un groupe C₁₆H₃₃.
10. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe (CH₂)_n-C₆H₅ dans lequel n a une valeur de 3 à 6, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe alkyle ou alcényle et X représente Cl⁻, Br⁻ ou I⁻.

11. Composés suivant la revendication 10, caractérisés en ce que R_1 représente un groupe $(CH_2)_3-C_6H_5$, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe $n-C_{12}H_{25}$ et X représente Cl^- , Br^- ou I^- .
- 5 12. Composés suivant la revendication 1, caractérisés en ce que R_1 représente un groupe $(CH_2)_4$, R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe $(C_{18}H_{35})_2CH$, X représente Cl^- , Br^- ou I^- et R_5 représente le groupe de la formule générale I, lié par R_1 , dans lequel R_2 et R_4 représentent l'hydrogène, R_3 représente un groupe $(C_{18}H_{35})_2CH$, et X représente Cl^- , Br^- ou I^- .
- 10 13. Composés suivant l'une des revendications précédentes, destinés à être utilisés comme outils pour introduire des macromolécules dans les cellules.
14. Composition pour introduire des macromolécules dans des cellules, comprenant des vésicules ou un autre type d'agrégat, formés par au moins un composé suivant l'une des revendications précédentes dans un solvant.
- 15 15. Composition suivant la revendication 14, caractérisée en ce qu'au moins une macromolécule est incorporée et/ou fixée aux vésicules.
16. Composition suivant la revendication 14 ou 15, caractérisée en ce que, en outre, au moins une molécule d'acheminement vers une cible est fixée aux vésicules.
- 20 17. Composition suivant la revendication 15, caractérisée en ce que la molécule d'acheminement vers une cible est un anticorps.
- 25 18. Composition suivant la revendication 16, caractérisée en ce que l'anticorps est marquée avec un marqueur radioactif ou est marquée avec de la streptavidine.

Transfection of COS-7 cells using different synthetic amphiphiles



Transfection of BHK cells using different synthetic amphiphiles



Vesicle-mediated versus CaP-mediated transfection

